223 related articles for article (PubMed ID: 24130096)
1. Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction.
Schaap M; Hancock R; Wilderspin A; Wells G
Protein Sci; 2013 Dec; 22(12):1812-9. PubMed ID: 24130096
[TBL] [Abstract][Full Text] [Related]
2. Protocol for a Steady-State FRET Assay in Cancer Chemoprevention.
Schaap MC; Guimarães AM; Wilderspin AF; Wells G
Methods Mol Biol; 2016; 1379():165-79. PubMed ID: 26608299
[TBL] [Abstract][Full Text] [Related]
3. Development of a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for the Inhibition of Keap1-Nrf2 Protein-Protein Interaction.
Lee S; Abed DA; Beamer LJ; Hu L
SLAS Discov; 2021 Jan; 26(1):100-112. PubMed ID: 32564647
[TBL] [Abstract][Full Text] [Related]
4. Optimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction.
Inoyama D; Chen Y; Huang X; Beamer LJ; Kong AN; Hu L
J Biomol Screen; 2012 Apr; 17(4):435-47. PubMed ID: 22156223
[TBL] [Abstract][Full Text] [Related]
5. Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction.
Hancock R; Bertrand HC; Tsujita T; Naz S; El-Bakry A; Laoruchupong J; Hayes JD; Wells G
Free Radic Biol Med; 2012 Jan; 52(2):444-51. PubMed ID: 22107959
[TBL] [Abstract][Full Text] [Related]
6. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling.
Lo SC; Li X; Henzl MT; Beamer LJ; Hannink M
EMBO J; 2006 Aug; 25(15):3605-17. PubMed ID: 16888629
[TBL] [Abstract][Full Text] [Related]
7. Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex.
Baird L; Llères D; Swift S; Dinkova-Kostova AT
Proc Natl Acad Sci U S A; 2013 Sep; 110(38):15259-64. PubMed ID: 23986495
[TBL] [Abstract][Full Text] [Related]
8. Development of a High-Throughput Cul3-Keap1 Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for Identifying Nrf2 Activators.
Poore DD; Hofmann G; Wolfe LA; Qi H; Jiang M; Fischer M; Wu Z; Sweitzer TD; Chakravorty S; Donovan B; Li H
SLAS Discov; 2019 Feb; 24(2):175-189. PubMed ID: 30383469
[TBL] [Abstract][Full Text] [Related]
9. Peptide and small molecule inhibitors of the Keap1-Nrf2 protein-protein interaction.
Wells G
Biochem Soc Trans; 2015 Aug; 43(4):674-9. PubMed ID: 26551711
[TBL] [Abstract][Full Text] [Related]
10. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
[TBL] [Abstract][Full Text] [Related]
11. Recapitulating the Binding Affinity of Nrf2 for KEAP1 in a Cyclic Heptapeptide, Guided by NMR, X-ray Crystallography, and Machine Learning.
Ortet PC; Muellers SN; Viarengo-Baker LA; Streu K; Szymczyna BR; Beeler AB; Allen KN; Whitty A
J Am Chem Soc; 2021 Mar; 143(10):3779-3793. PubMed ID: 33683866
[TBL] [Abstract][Full Text] [Related]
12. Drug screening assay based on the interaction of intact Keap1 and Nrf2 proteins in cancer cells.
Zhou B; Zhang X; Wang G; Barbour KW; Berger FG; Wang Q
Bioorg Med Chem; 2019 Jan; 27(1):92-99. PubMed ID: 30473361
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
[TBL] [Abstract][Full Text] [Related]
14. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
16. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
Shibata T; Ohta T; Tong KI; Kokubu A; Odogawa R; Tsuta K; Asamura H; Yamamoto M; Hirohashi S
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13568-73. PubMed ID: 18757741
[TBL] [Abstract][Full Text] [Related]
17. Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2-related factors 1 and 2 (NRF1 and NRF2).
Tian W; Rojo de la Vega M; Schmidlin CJ; Ooi A; Zhang DD
J Biol Chem; 2018 Feb; 293(6):2029-2040. PubMed ID: 29255090
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of Keap1 interactions with Nrf2.
Canning P; Sorrell FJ; Bullock AN
Free Radic Biol Med; 2015 Nov; 88(Pt B):101-107. PubMed ID: 26057936
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Binding Energy of Keap1 Interaction Motifs in the Nrf2 Antioxidant Pathway and Design of Potential High-Affinity Peptides.
Karttunen M; Choy WY; Cino EA
J Phys Chem B; 2018 Jun; 122(22):5851-5859. PubMed ID: 29745220
[TBL] [Abstract][Full Text] [Related]
20. Crystal-contact engineering to obtain a crystal form of the Kelch domain of human Keap1 suitable for ligand-soaking experiments.
Hörer S; Reinert D; Ostmann K; Hoevels Y; Nar H
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2013 Jun; 69(Pt 6):592-6. PubMed ID: 23722832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
